Physician profile
Jared Dixon
NPI 1780833707
$12,863.58
in general payments reported to CMS, 2019-2025
59 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,057 · 2020: $1,580 · 2021: $2,073 · 2022: $1,770 · 2023: $1,985 · 2024: $1,784 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,373 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,372.58 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,653.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,592.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,247.90 | 2019-2025 | |
| Abbvie INC. | $1,089.37 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $676.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $532.07 | 2019-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $511.78 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Amgen INC. | $403.22 | 2019-2025 | Evenity, Prolia, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $396.11 | 2019-2022 | |
| Dexcom, INC. | $384.63 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $355.76 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.67 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $347.87 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $292.29 | 2019-2024 | Belsomra, Verquvo, Capvaxive |
| Amarin Pharma, INC. | $289.24 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.